Participating for Nine Consecutive Years with an Exclusive Booth
Introducing Molecule-Specific Customized Process Design

Samsung Biologics announced on the 28th that it participated in the global biopharmaceutical industry conference, "2026 BioProcess International (BPI)," where it introduced strategies for innovation in biopharmaceutical manufacturing processes.

Lee Taehee, Executive Director and Head of Antibody Cell Purification Process Development Team at Samsung Biologics, is giving a lecture at an expert presentation session on the 23rd (local time). Samsung Biologics

Lee Taehee, Executive Director and Head of Antibody Cell Purification Process Development Team at Samsung Biologics, is giving a lecture at an expert presentation session on the 23rd (local time). Samsung Biologics

View original image

BPI is an event that covers all areas of biopharmaceutical development, production, and analysis, where the latest technologies are shared and partnerships are discussed. This year's event, held in Boston, USA from September 22 to 25 (local time), brought together more than 250 companies and over 3,000 global biopharmaceutical experts from around the world.


Samsung Biologics, which has participated in BPI for nine consecutive years since 2018, set up an exclusive booth again this year to showcase its capabilities supporting the entire lifecycle of biopharmaceuticals, from Contract Research Organization (CRO) to Contract Development Organization (CDO) and Contract Manufacturing Organization (CMO). In particular, using a wall graphic at its booth, Samsung Biologics highlighted its key competitive strengths, including Samsung Organoid, differentiated CDO capabilities, and multimodality manufacturing.


Expert presentations and poster sessions were also held to showcase Samsung Biologics' technological competitiveness. On the 23rd, Lee Taehee, Executive Director and Head of Antibody Cell Purification Process Development Team, delivered a presentation titled "From Complexity to Confidence." Lee disclosed a case in which the company designed molecule-specific customized processes based on integrated Chemistry, Manufacturing, and Controls (CMC), shortening the development period from the typical 13 months to 9.5 months while maintaining high quality.


At the poster session, various process innovation achievements of Samsung Biologics were introduced as well. Kim Younghee, Head of Cell Line Development Group, presented strategies for simultaneously controlling both product quality and efficacy from the early stages of cell line development, under the theme of "A Streamlined Cell Line Development Platform for Complex Molecules." Lee Sojung, Head of Cell Culture Process Development Group, introduced the enhanced cell culture process platform "S-Tensify™," which allows for increased cell density during cultivation, thereby doubling the titer compared to previous levels while maintaining the highest quality standards.


In addition, Samsung Biologics also participated in the simultaneously held "International Society for Cell & Gene Therapy" at the BPI venue, presenting standards for accurately measuring the quality of advanced viral therapeutics.



James Choi, Head of Sales Support at Samsung Biologics, said, "It is a meaningful opportunity to showcase our unparalleled end-to-end support capabilities and differentiated technological strengths in biopharmaceuticals, from CRO to CDO and CMO, through BPI. We will continue to solidify our position in the global biopharmaceutical market with advanced technologies and services."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing